ACTRN12617000824369CompletedPhase 1
Safety and Immunogenicity Study of a Genetically Attenuated Malaria Vaccine candidate in healthy volunteers
QIMR Berghofer Medical Research Institute0 sites6 target enrollmentStarted: June 6, 2017Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Enrollment
- 6
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 Years to 55 Years (—)
- Sex
- Male
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Similar Trials
Completed
Phase 1
Reactogenicity and Immunogenicity of the pentavalent vaccine DPT-HB+Hib. Schedule 2-4-6 months.Prophylaxis against infections diseases: Diphtheria, Tetanus, B. pertussis, H. influenzae type b and hepatitis B.RPCEC00000103Center for Genetic Engineering and Biotechnology (CIGB).624
Not yet recruiting
Phase 1
ABDALA Clinical StudyCOVID-19SARS-CoV2Disease PreventionCoronavirus InfectionsSARS VirusCoronaviridae InfectionsBetacoronavirusRPCEC00000346Center for Genetic Engineering and Biotechnology (CIGB), in Havana
Not yet recruiting
Phase 1
Safety and immunogenicity of VCN7-T in infants of 2 and 3 months. Phase I/II.Pneumococcal diseaseHealthy VolunteersPneumococcal InfectionsStreptococcal InfectionsGram-Positive Bacterial InfectionsRPCEC00000243Finlay Institute Vaccine880
Completed
Phase 1
Investigating of the Immunogenicity and Safety of Lactococcus Lactis Vaccine Related to Human Papillomavirus Type 16IRCT20190504043464N1Iran University of Medical Sciences200
Completed
Not Applicable
Evaluation of a prototype vaccine against enterotoxigenic Escherichia coli diarrhoeaEnterotoxigenic E. coli (ETEC) diarrhoeaInfections and InfestationsEnterotoxigenic Escherichia coli infectionISRCTN23764070Gothenburg University Vaccine Research Institute (GUVAX) (Sweden)60